Generation Bio Co. (GBIO)
After hours:
| Previous Close | 5.01 |
| Open | 4.93 |
| Bid | 4.84 x 1100 |
| Ask | 5.20 x 800 |
| Day's Range | 4.84 - 5.22 |
| 52 Week Range | 3.96 - 15.59 |
| Volume | |
| Avg. Volume | 180,996 |
| Market Cap | 303.65M |
| Beta (5Y Monthly) | 1.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.27 |
| Earnings Date | Feb 22, 2023 - Feb 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.67 |
- Zacks
Can Generation Bio Co. (GBIO) Climb 184% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 183.8% in Generation Bio Co. (GBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- Zacks
Wall Street Analysts Think Generation Bio Co. (GBIO) Could Surge 176%: Read This Before Placing a Bet
The consensus price target hints at a 176% upside potential for Generation Bio Co. (GBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- GlobeNewswire
Generation Bio Reports Business Highlights and Third Quarter 2022 Financial Results
Cash balance of $301.2M expected to fund operations into 2025CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and third quarter 2022 financial results. “Generation Bio’s mission is to unlock the full promise of genetic medicine by developing novel durable, redosable and titratable DNA therapeutics,” said Geoff McDonough, M.D.,
